Mind + Muscle

technical minds + legal muscle


dig deep

Federal Circuit Affirms a Separate Written Description Requirement from the Enablement Requirement

  • 03.23.10
  • Sterne, Kessler, Goldstein & Fox

On March 22, 2010, the U.S. Court of Appeals for the Federal Circuit decided Ariad Pharmaceuticals Inc. v. Eli Lilly & Co., No. 2008-1248 (Fed. Cir. 2010)(en banc), affirming that a written description requirement exists separately from the enablement requirement under 35 U.S.C. § 112, first paragraph.

This highly-anticipated decision considered the following fundamental issues related to the written description requirement for patentability under 35 U.S.C. § 112, first paragraph:

  • Whether 35 U.S.C. § 112, first paragraph, contains a written description requirement separate from an enablement requirement?
  • If a separate written description requirement is set forth in the statute, what is the scope and purpose of the requirement?

Download the PDF for a more detailed discussion of the decision.

Related People

Related Services

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.